Key Insights

Highlights

Success Rate

84% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.4%

5 terminated out of 68 trials

Success Rate

83.9%

-2.6% vs benchmark

Late-Stage Pipeline

19%

13 trials in Phase 3/4

Results Transparency

23%

6 of 26 completed with results

Key Signals

6 with results84% success

Data Visualizations

Phase Distribution

54Total
Not Applicable (30)
Early P 1 (1)
P 1 (2)
P 2 (8)
P 3 (9)
P 4 (4)

Trial Status

Completed26
Unknown14
Recruiting11
Not Yet Recruiting6
Terminated5
Active Not Recruiting4

Trial Success Rate

83.9%

Benchmark: 86.5%

Based on 26 completed trials

Clinical Trials (68)

Showing 20 of 20 trials
NCT07207226Not ApplicableActive Not RecruitingPrimary

Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension

NCT06344104Phase 3Completed

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT05464849Completed

Evaluation of Systemic Microvascular Reactivity in Patients With Resistant Hypertension

NCT06169241Early Phase 1Recruiting

Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients

NCT06880562Not ApplicableNot Yet RecruitingPrimary

The RESPLASH Study

NCT04388124Phase 2RecruitingPrimary

Endothelin-1 Receptor Blockade in Resistant Hypertension

NCT06829537CompletedPrimary

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

NCT06168409Phase 3CompletedPrimary

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

NCT07383220Not ApplicableRecruitingPrimary

Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure

NCT05888233Phase 2Recruiting

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

NCT05562934Phase 2CompletedPrimary

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

NCT06216808Not ApplicableRecruitingPrimary

A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension

NCT06526858Not ApplicableRecruitingPrimary

Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

NCT07232966Phase 3Not Yet RecruitingPrimary

Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension

NCT07081243RecruitingPrimary

Symplicity China Study

NCT06034743Phase 3Completed

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT05563077Not ApplicableActive Not RecruitingPrimary

Aerobic Exercise and Resistant Hypertension

NCT04637152Phase 2CompletedPrimary

Sacubitril/Valsartan in Resistant Hypertension

NCT06780696Not Yet Recruiting

SMART Study in Real World

NCT06819241Not ApplicableNot Yet RecruitingPrimary

Self-Management of Blood Pressure in Resistant Hypertension

Scroll to load more

Research Network

Activity Timeline